Farmas USA

FB recuperando y se acerca otra vez a los 26'XX

mirate esta que recomendó Pedro at: ASTM
yo dejé orden en 1.21, pero no entró. ;-((((

¡Zalicus va disparada cuesta arriba!
0.69 (±16%) superándose y aún tiene ganas de más.

0,71 !!!!
Venga que os quiero a 0,90 Auuu !!! Auuuuu !!!
ZLCS

Vamos a tapar ese gap!
ZALICUS

http://finance.yahoo.com/news/zalicus-z160-chronic-neuropathic-pain-130000163.html

Zalicus Inc. (ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in Phase 2 clinical development for chronic neuropathic pain, has been chosen by Windhover as one of the Top 10 Neuroscience Projects to Watch. Mark Corrigan, MD, CEO of Zalicus, will provide a summary of Z160 during his presentation at the Windhover 2012 Therapeutic Area Partnership meeting being held at the Westin Copley Place Boston at 1:30 p.m. ET on Thursday, November 29, 2012 during the Top 10 Neuroscience Projects to Watch session.

"We are delighted that Z160 has been selected as a Top 10 Project to Watch,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “The lack of adequate pain control in patients with chronic neuropathic pain represents a significant unmet need and important opportunity for novel agents with improved tolerability, enhanced efficacy, and better long-term safety profiles. We look forward to providing further updates on the clinical development of Z160 over the coming months.”

Noticia de hace unos minutillos la cual nos cuenta lo que ya sabíamos, el añadido de ZLCS a la lista del top 10 de proyectos de Neurociencia a vigilar:
"Zalicus Inc. (Nasdaq: ZLCS) 13.6% HIGHER; announced that Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker in Phase 2 clinical development for chronic neuropathic pain, has been chosen by Windhover as one of the Top 10 Neuroscience Projects to Watch. Mark Corrigan, MD, CEO of Zalicus, will provide a summary of Z160 during his presentation at the Windhover 2012 Therapeutic Area Partnership meeting being held at the Westin Copley Place Boston at 1:30 p.m. ET on Thursday, November 29, 2012 during the Top 10 Neuroscience Projects to Watch session. "

Fuente: Streetinsider.com

Pues nada, acumulando CELSION a 7,25 ... que no me arrepienta .

El viernes pasado ya comente algo sobre FOLD,parece que tiene ganas.
http://www.google.com/finance?q=NASDAQ%3AFOLD&ei=GAy1UKCZAuX5wAPf9wE

http://finance.yahoo.com/news/hot-biopharma-stocks-move-tuesday-173003204.html